510(K) clearance for Cortecs' Helicobacter pylori test:
This article was originally published in Clinica
Executive Summary
Cortecs has received clearance from the FDA to market its rapid test for the bacteria Helicobacter pylori in the US to hospitals, clinical laboratories and some doctors' offices. The company has also applied for a waiver under the Clinical Laboratories Improvements Amendment to sell the test to the remaining doctors' offices in the US. Becton Dickinson will distribute both the H pylori test and another test for glandular fever in that country.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.